CytoSorbents Corporation announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections. This multi-year agreement includes all critical care applications in Vietnam, and is subject to annual minimum purchases of CytoSorb(r) to maintain exclusivity.
End-of-day quote
Other stock markets
|
||
- | - |
|
2023 | Hoang Long Group Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2023 | Hoang Long Group Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 | CI |
1st Jan change | Capi. | |
---|---|---|
-5.14% | 8.36B | |
-2.06% | 6.97B | |
-0.43% | 2.35B | |
+11.70% | 1.63B | |
+10.18% | 1.54B | |
-3.75% | 914M | |
+1.65% | 886M | |
+18.06% | 645M | |
+181.15% | 509M |
- Stock Market
- Equities
- Stock
- News Hoang Long Group
- Cytosorbents Corporation and Hoang Long Group Announces Distribution Agreement